Maternal Plasma Fetal DNA Fractions in Pregnancies with Low and High Risks for Fetal Chromosomal Aneuploidies

Recently published international guidelines recommend the clinical use of noninvasive prenatal test (NIPT) for aneuploidy screening only among pregnant women whose fetuses are deemed at high risk. The applicability of NIPT to aneuploidy screening among average risk pregnancies requires additional supportive evidence. A key determinant of the reliability of aneuploidy NIPT is the fetal DNA fraction in maternal plasma. In this report, we investigated if differences in fetal DNA fractions existed between different pregnancy risk groups. One hundred and ninety-five singleton pregnancies with male fetuses divided into 3 groups according to first trimester screening parameters were examined for fetal DNA percentage by counting Y chromosome DNA sequences using massively parallel sequencing. Fetal DNA fractions were compared between risk groups and assessed for correlations with first trimester screening parameters. There was no statistically significant difference in fetal DNA fractions across the high, intermediate and low risk groups. Fetal DNA fraction showed a strong negative correlation with maternal weight. Fetal DNA fraction also showed weak but significant correlations with gestational age, crown-rump length, multiple of medians of free β-subunit of human chorionic gonadotropin and pregnancy-associated plasma protein A. Similar fetal DNA fractions in maternal plasma between high, intermediate and low risk pregnant women is a precondition for uniform performance of the aneuploidy NIPTs for the general population. This study thus shows that the aneuploidy screening by NIPT is likely to offer similar analytical reliability without respect to the a priori fetal aneuploidy risk.

[1]  B. Crandall,et al.  INCIDENCE AND SIGNIFICANCE OF CHROMOSOME MOSAICISM INVOLVING AN AUTOSOMAL STRUCTURAL ABNORMALITY DIAGNOSED PRENATALLY THROUGH AMNIOCENTESIS: A COLLABORATIVE STUDY , 1996, Prenatal diagnosis.

[2]  J. Dungan,et al.  Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study , 2011 .

[3]  S N Erné,et al.  Multi‐channel magnetocardiography for detecting beat morphology variations in fetal arrhythmias , 2004, Prenatal diagnosis.

[4]  K. Nicolaides,et al.  Fetal fraction in maternal plasma cell‐free DNA at 11–13 weeks' gestation: relation to maternal and fetal characteristics , 2013, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[5]  Jian Wang,et al.  Clinical application of massively parallel sequencing‐based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11 105 pregnancies with mixed risk factors , 2012, Prenatal diagnosis.

[6]  M. Watson,et al.  ACMG statement on noninvasive prenatal screening for fetal aneuploidy , 2013, Genetics in Medicine.

[7]  Hanmin Lee,et al.  Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. , 2012, American journal of obstetrics and gynecology.

[8]  A. Kurjak,et al.  Noninvasive Prenatal Testing for Fetal Aneuploidy , 2013 .

[9]  Yama W. L. Zheng,et al.  Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study , 2011, BMJ : British Medical Journal.

[10]  Arnold Oliphant,et al.  Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. , 2012, American journal of obstetrics and gynecology.

[11]  Stanley F. Nelson,et al.  DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study , 2012, Genetics in Medicine.

[12]  K. Nicolaides,et al.  Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. , 2012, American journal of obstetrics and gynecology.

[13]  T. Musci,et al.  Clinical experience of noninvasive prenatal testing with cell‐free DNA for fetal trisomies 21, 18, and 13, in a general screening population , 2013, Prenatal diagnosis.

[14]  K. Nicolaides,et al.  Validation of targeted sequencing of single‐nucleotide polymorphisms for non‐invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y , 2013, Prenatal diagnosis.

[15]  T K Lau,et al.  Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. , 1998, American journal of human genetics.

[16]  C. Struble,et al.  The fetal fraction of cell-free DNA in maternal plasma is not affected by a priori risk of fetal trisomy , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[17]  D. Sahota,et al.  Comparison of likelihood ratios of first‐trimester nuchal translucency measurements: multiples of median, delta or mixture , 2010, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[18]  Lin Tang,et al.  Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. , 2011, American journal of obstetrics and gynecology.

[19]  K. Nicolaides,et al.  Fetal Fraction in Maternal Plasma Cell-Free DNA at 11–13 Weeks’ Gestation: Effect of Maternal and Fetal Factors , 2012, Fetal Diagnosis and Therapy.

[20]  J. Canick,et al.  The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies , 2013, Prenatal diagnosis.

[21]  L. Dugoff,et al.  Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis , 2013, Prenatal diagnosis.